Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Reply to Letters to Editor re: GASTRO-D- 19-00618 et al.

Bernstein CN.

Gastroenterology. 2019 Sep 9. pii: S0016-5085(19)41305-X. doi: 10.1053/j.gastro.2019.08.046. [Epub ahead of print] No abstract available.

PMID:
31513798
2.

Geographical Variation and Factors Associated With Inflammatory Bowel Disease in a Central Canadian Province.

Torabi M, Bernstein CN, Yu BN, Wickramasinghe L, Blanchard JF, Singh H.

Inflamm Bowel Dis. 2019 Aug 23. pii: izz168. doi: 10.1093/ibd/izz168. [Epub ahead of print]

PMID:
31504519
3.

Inflammatory bowel disease patient profiles are related to specific information needs: A nationwide survey.

Daher S, Khoury T, Benson A, Walker JR, Hammerman O, Kedem R, Naftali T, Eliakim R, Ben-Bassat O, Bernstein CN, Israeli E.

World J Gastroenterol. 2019 Aug 14;25(30):4246-4260. doi: 10.3748/wjg.v25.i30.4246.

4.

The Use of Capsule Endoscopy For Diagnosis of Iron Deficiency Anemia: A Retrospective Analysis.

Stone J, Grover K, Bernstein CN.

J Clin Gastroenterol. 2019 Aug 1. doi: 10.1097/MCG.0000000000001255. [Epub ahead of print]

PMID:
31373940
5.

A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD.

Elias ED, Targownik LE, Singh H, Bernstein CN.

Inflamm Bowel Dis. 2019 Jul 24. pii: izz148. doi: 10.1093/ibd/izz148. [Epub ahead of print]

PMID:
31340002
6.

Genome-wide copy number variant data for inflammatory bowel disease in a caucasian population.

Frenkel S, Bernstein CN, Jin YW, Sargent M, Kuang Q, Jiang W, Wei J, Thiruvahindrapuram B, Scherer SW, Hu P.

Data Brief. 2019 Jul 2;25:104203. doi: 10.1016/j.dib.2019.104203. eCollection 2019 Aug.

7.

Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.

El-Matary W, Leung S, Tennakoon A, Benchimol EI, Bernstein CN, Targownik LE.

Inflamm Bowel Dis. 2019 Jul 19. pii: izz157. doi: 10.1093/ibd/izz157. [Epub ahead of print]

PMID:
31323083
8.

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada.

Rose KL, Sherman PM, Cooke-Lauder J, Mawani M, Benchimol EI, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S81-S91. doi: 10.1093/jcag/gwy057. Epub 2018 Nov 2.

9.

The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.

Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.

10.

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.

Nguyen GC, Targownik LE, Singh H, Benchimol EI, Bitton A, Murthy SK, Bernstein CN, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2.

11.

The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.

Carroll MW, Kuenzig ME, Mack DR, Otley AR, Griffiths AM, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.

12.

The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life.

Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S42-S48. doi: 10.1093/jcag/gwy048. Epub 2018 Nov 2.

13.

The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.

Kuenzig ME, Lee L, El-Matary W, Weizman AV, Benchimol EI, Kaplan GG, Nguyen GC, Bernstein CN, Bitton A, Lee K, Cooke-Lauder J, Murthy SK.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2.

14.

The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.

15.

The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.

Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2.

16.

The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada.

Benchimol EI, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Siddiq S, Windsor JW, Carroll MW, Coward S, El-Matary W, Griffiths AM, Jones JL, Kuenzig ME, Lee L, Mack DR, Mawani M, Otley AR, Singh H, Targownik LE, Weizman AV, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S1-S5. doi: 10.1093/jcag/gwy052. Epub 2018 Nov 2.

17.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

J Can Assoc Gastroenterol. 2019 Aug;2(3):e1-e34. doi: 10.1093/jcag/gwz019. Epub 2018 Jul 10.

18.

Addressing Mental Health in Persons with IBD.

Bernstein CN.

J Can Assoc Gastroenterol. 2018 Sep;1(3):97-98. doi: 10.1093/jcag/gwy038. Epub 2018 Jul 17. No abstract available.

19.

Is Antibiotic Use a Cause of IBD Worldwide?

Bernstein CN.

Inflamm Bowel Dis. 2019 Jul 2. pii: izz138. doi: 10.1093/ibd/izz138. [Epub ahead of print] No abstract available.

PMID:
31265061
20.

The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases.

Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN.

Am J Gastroenterol. 2019 Jul;114(7):1051-1070. doi: 10.14309/ajg.0000000000000305.

PMID:
31232832
21.

The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.

Targownik LE, Benchimol EI, Witt J, Bernstein CN, Singh H, Lix L, Tennakoon A, Zubieta AA, Coward S, Jones J, Kuenzig E, Murthy SK, Nguyen GC, Peña-Sánchez JN, Kaplan G.

Inflamm Bowel Dis. 2019 Jun 18. pii: izz063. doi: 10.1093/ibd/izz063. [Epub ahead of print]

PMID:
31211836
22.

The validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis.

Hitchon CA, Zhang L, Peschken CA, Lix LM, Graff LA, Fisk JD, Patten SB, Bolton J, Sareen J, El-Gabalawy R, Marriott J, Bernstein CN, Marrie R.

Arthritis Care Res (Hoboken). 2019 Jun 14. doi: 10.1002/acr.24011. [Epub ahead of print]

PMID:
31199570
23.

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.

Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M.

Gut. 2019 Jun 12. pii: gutjnl-2019-318440. doi: 10.1136/gutjnl-2019-318440. [Epub ahead of print]

24.

Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies.

Samarani S, Mack DR, Bernstein CN, Iannello A, Debbeche O, Jantchou P, Faure C, Deslandres C, Amre DK, Ahmad A.

PLoS One. 2019 Jun 13;14(6):e0217767. doi: 10.1371/journal.pone.0217767. eCollection 2019.

25.

Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease.

Frenkel S, Bernstein CN, Sargent M, Kuang Q, Jiang W, Wei J, Thiruvahindrapuram B, Spriggs E, Scherer SW, Hu P.

PLoS One. 2019 Jun 11;14(6):e0217846. doi: 10.1371/journal.pone.0217846. eCollection 2019.

26.

Semaphorin 3E regulates apoptosis in the intestinal epithelium during the development of colitis.

Eissa N, Hussein H, Diarra A, Elgazzar O, Gounni AS, Bernstein CN, Ghia JE.

Biochem Pharmacol. 2019 Aug;166:264-273. doi: 10.1016/j.bcp.2019.05.029. Epub 2019 Jun 3.

PMID:
31170375
27.

Information experiences, needs, and preferences of colonoscopy patients: A pre-colonoscopy survey.

Lee E, Shafer LA, Walker JR, Waldman C, Michaud V, Yang C, Bernstein CN, Hathout L, Park J, Sisler J, Wittmeier K, Restall G, Singh H.

Medicine (Baltimore). 2019 May;98(20):e15738. doi: 10.1097/MD.0000000000015738.

28.

Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study.

Shafer LA, Walker JR, Chhibba T, Targownik LE, Singh H, Ivekovic M, Bernstein CN.

Inflamm Bowel Dis. 2019 May 14. pii: izz102. doi: 10.1093/ibd/izz102. [Epub ahead of print]

PMID:
31087034
29.

Copy number variation-based gene set analysis reveals cytokine signalling pathways associated with psychiatric comorbidity in patients with inflammatory bowel disease.

Frenkel S, Bernstein CN, Sargent M, Jiang W, Kuang Q, Xu W, Hu P.

Genomics. 2019 May 7. pii: S0888-7543(19)30081-3. doi: 10.1016/j.ygeno.2019.05.001. [Epub ahead of print]

PMID:
31075388
30.

Sorting Through the Risks and Benefits of Thiopurine Therapy for Inflammatory Bowel Diseases.

Singh H, Bernstein CN.

Clin Gastroenterol Hepatol. 2019 Apr 28. pii: S1542-3565(19)30437-9. doi: 10.1016/j.cgh.2019.04.047. [Epub ahead of print] No abstract available.

PMID:
31042576
31.

Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.

Marrie RA, Walker JR, Graff LA, Patten SB, Bolton JM, Marriott JJ, Fisk JD, Hitchon C, Peschken C, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Patient Educ Couns. 2019 Sep;102(9):1722-1729. doi: 10.1016/j.pec.2019.04.007. Epub 2019 Apr 6.

32.

The Relationship Between Adverse Childhood Experiences and Health Care Use in the Manitoba IBD Cohort Study.

Witges KM, Bernstein CN, Sexton KA, Afifi T, Walker JR, Nugent Z, Lix LM.

Inflamm Bowel Dis. 2019 Mar 23. pii: izz054. doi: 10.1093/ibd/izz054. [Epub ahead of print]

PMID:
30919910
33.

The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application.

Sexton KA, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie BE, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1277-1290. doi: 10.1093/ibd/izz038.

PMID:
30918969
34.

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease.

Lewis K, Marrie RA, Bernstein CN, Graff LA, Patten SB, Sareen J, Fisk JD, Bolton JM; CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease .

Inflamm Bowel Dis. 2019 Mar 19. pii: izz045. doi: 10.1093/ibd/izz045. [Epub ahead of print]

PMID:
30888037
35.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1680-1713. doi: 10.1016/j.cgh.2019.02.043. Epub 2019 Mar 7.

PMID:
30853616
36.

Accommodations and Adaptations to Overcome Workplace Disability in Inflammatory Bowel Disease Patients: A Systematic Review.

Paulides E, Gearry RB, de Boer NKH, Mulder CJJ, Bernstein CN, McCombie AM.

Inflamm Intest Dis. 2019 Feb;3(3):138-144. doi: 10.1159/000495293. Epub 2019 Jan 3.

37.

Events Within the First Year of Life, but Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases.

Bernstein CN, Burchill C, Targownik LE, Singh H, Roos LL.

Gastroenterology. 2019 Jun;156(8):2190-2197.e10. doi: 10.1053/j.gastro.2019.02.004. Epub 2019 Feb 14.

PMID:
30772341
38.

Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C+ and CD4+ CD25- T-cells.

Kermarrec L, Eissa N, Wang H, Kapoor K, Diarra A, Gounni AS, Bernstein CN, Ghia JE.

Br J Pharmacol. 2019 May;176(9):1235-1250. doi: 10.1111/bph.14614. Epub 2019 Apr 1.

PMID:
30736100
39.

A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?

Forbes JD, Bernstein CN, Tremlett H, Van Domselaar G, Knox NC.

Front Microbiol. 2019 Jan 9;9:3249. doi: 10.3389/fmicb.2018.03249. eCollection 2018. Review.

40.

The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?

Knox NC, Forbes JD, Van Domselaar G, Bernstein CN.

Curr Treat Options Gastroenterol. 2019 Mar;17(1):115-126. doi: 10.1007/s11938-019-00221-w. Review.

PMID:
30661163
41.

Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data.

Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, Carroll MW, Hazlewood G, Jacobson K, Jelinski S, Deardon R, Jones JL, Kuenzig ME, Leddin D, McBrien KA, Murthy SK, Nguyen GC, Otley AR, Panaccione R, Rezaie A, Rosenfeld G, Peña-Sánchez JN, Singh H, Targownik LE, Kaplan GG.

Gastroenterology. 2019 Apr;156(5):1345-1353.e4. doi: 10.1053/j.gastro.2019.01.002. Epub 2019 Jan 10.

42.

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Neurology. 2019 Jan 11. pii: 10.1212/WNL.0000000000006854. doi: 10.1212/WNL.0000000000006854. [Epub ahead of print]

PMID:
30635487
43.

A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G.

Microbiome. 2018 Dec 13;6(1):221. doi: 10.1186/s40168-018-0603-4.

44.

Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.

Benchimol EI, Kuenzig ME, Bernstein CN, Nguyen GC, Guttmann A, Jones JL, Potter BK, Targownik LE, Catley CA, Nugent ZJ, Tanyingoh D, Mojaverian N, Underwood FE, Siddiq S, Otley AR, Bitton A, Carroll MW, deBruyn JC, Dummer TJ, El-Matary W, Griffiths AM, Jacobson K, Leddin D, Lix LM, Mack DR, Murthy SK, Peña-Sánchez JN, Singh H, Kaplan GG; Canadian Gastro-Intestinal Epidemiology Consortium.

Clin Epidemiol. 2018 Nov 8;10:1613-1626. doi: 10.2147/CLEP.S178056. eCollection 2018.

45.

Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.

Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-Sánchez JN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15.

PMID:
30448599
46.

Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study.

El-Matary W, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN, Singh H.

J Pediatr. 2019 Mar;206:20-25. doi: 10.1016/j.jpeds.2018.10.041. Epub 2018 Nov 15.

PMID:
30448272
47.

Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations.

Witges K, Targownik LE, Haviva C, Walker JR, Graff LA, Sexton KA, Lix L, Sargent M, Vagianos K, Bernstein CN.

JMIR Res Protoc. 2018 Nov 12;7(11):e11317. doi: 10.2196/11317.

48.

Diabetes and anxiety adversely affect cognition in multiple sclerosis.

Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff L, Mazerolle EL, Marriott JJ, Bernstein CN, Fisk JD; Comorbidity and Cognition in Multiple Sclerosis (CCOMS) Study Group.

Mult Scler Relat Disord. 2019 Jan;27:164-170. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

49.

Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.

Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1807-1813.e1. doi: 10.1016/j.cgh.2018.09.038. Epub 2018 Sep 26.

PMID:
30267862
50.

Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.

Gasim M, Bernstein CN, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Marrie RA; CIHR team “Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease”.

Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12.

Supplemental Content

Loading ...
Support Center